Literature DB >> 24280983

A model for streamlining psychotherapy in the RDoC era: the example of 'Engage'.

G S Alexopoulos1, P Arean2.   

Abstract

A critical task for psychotherapy research is to create treatments that can be used by community clinicians. Streamlining of psychotherapies is a necessary first step for this purpose. We suggest that neurobiological knowledge has reached the point of providing biologically meaningful behavioral targets, thus guiding the development of effective, simplified psychotherapies. This view is supported by the Research Domain Criteria (RDoC) Project, which reflects the field's consensus and recognizes the readiness of neurobiology to guide research in treatment development. 'Engage' is an example of such a streamlined therapy. It targets behavioral domains of late-life depression grounded on RDoC constructs using efficacious behavioral strategies selected for their simplicity. 'Reward exposure' targeting the behavioral expression of positive valence systems' dysfunction is the principal therapeutic vehicle of 'Engage'. Its first three sessions consist of direct 'reward exposure', but the therapists search for barriers in three behavioral domains, that is, 'negativity bias' (negative valence), 'apathy' (arousal) and 'emotional dysregulation' (cognitive control), and add strategies targeting these domains when needed. The end result is a structured, stepped approach using neurobiological constructs as targets and as a guide to personalization. We argue that the 'reduction' process needed in order to arrive to simplified effective therapies can be achieved in three steps: (1) identify RDoC constructs driving the syndrome's psychopathology; (2) create a structured intervention utilizing behavioral and ecosystem modification techniques targeting behaviors related to these constructs; (3) examine whether the efficacy of the new intervention is mediated by change in behaviors related to the targeted RDoC constructs.

Entities:  

Mesh:

Year:  2013        PMID: 24280983      PMCID: PMC4337206          DOI: 10.1038/mp.2013.150

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  81 in total

1.  Measurement-based care for unipolar depression.

Authors:  David W Morris; Madhukar H Trivedi
Journal:  Curr Psychiatry Rep       Date:  2011-12       Impact factor: 5.285

2.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

Review 3.  Apathy in neuropsychiatric disease: diagnosis, pathophysiology, and treatment.

Authors:  Thomas N Chase
Journal:  Neurotox Res       Date:  2010-05-15       Impact factor: 3.911

4.  DeltaFosB in brain reward circuits mediates resilience to stress and antidepressant responses.

Authors:  Vincent Vialou; Alfred J Robison; Quincey C Laplant; Herbert E Covington; David M Dietz; Yoshinori N Ohnishi; Ezekiell Mouzon; Augustus J Rush; Emily L Watts; Deanna L Wallace; Sergio D Iñiguez; Yoko H Ohnishi; Michel A Steiner; Brandon L Warren; Vaishnav Krishnan; Carlos A Bolaños; Rachael L Neve; Subroto Ghose; Olivier Berton; Carol A Tamminga; Eric J Nestler
Journal:  Nat Neurosci       Date:  2010-05-16       Impact factor: 24.884

5.  Ventral striatum response during reward and punishment reversal learning in unmedicated major depressive disorder.

Authors:  Oliver J Robinson; Roshan Cools; Christina O Carlisi; Barbara J Sahakian; Wayne C Drevets
Journal:  Am J Psychiatry       Date:  2012-02       Impact factor: 18.112

6.  Activity scheduling as a core component of effective care management for late-life depression.

Authors:  Genevieve Riebe; Ming-Yu Fan; Jürgen Unützer; Steven Vannoy
Journal:  Int J Geriatr Psychiatry       Date:  2012-02-27       Impact factor: 3.485

7.  Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care.

Authors:  Madhukar H Trivedi; A John Rush; Bradley N Gaynes; Jonathan W Stewart; Stephen R Wisniewski; Diane Warden; Louise Ritz; James F Luther; Diane Stegman; Joanne Deveaugh-Geiss; Robert Howland
Journal:  Neuropsychopharmacology       Date:  2007-04-04       Impact factor: 7.853

8.  Amygdala and nucleus accumbens activation to emotional facial expressions in children and adolescents at risk for major depression.

Authors:  Christopher S Monk; Rachel G Klein; Eva H Telzer; Elizabeth A Schroth; Salvatore Mannuzza; John L Moulton; Mary Guardino; Carrie L Masten; Erin B McClure-Tone; Stephen Fromm; R James Blair; Daniel S Pine; Monique Ernst
Journal:  Am J Psychiatry       Date:  2007-11-06       Impact factor: 18.112

9.  The role of the nucleus accumbens and rostral anterior cingulate cortex in anhedonia: integration of resting EEG, fMRI, and volumetric techniques.

Authors:  Jan Wacker; Daniel G Dillon; Diego A Pizzagalli
Journal:  Neuroimage       Date:  2009-02-06       Impact factor: 6.556

10.  Neural Changes following Behavioral Activation for a Depressed Breast Cancer Patient: A Functional MRI Case Study.

Authors:  Michael J Gawrysiak; John P Carvalho; Baxter P Rogers; Christopher R N Nicholas; John H Dougherty; Derek R Hopko
Journal:  Case Rep Psychiatry       Date:  2012-05-09
View more
  37 in total

1.  "Engage" Therapy: Behavioral Activation and Improvement of Late-Life Major Depression.

Authors:  George S Alexopoulos; Patrick J Raue; Faith Gunning; Dimitris N Kiosses; Dora Kanellopoulos; Cristina Pollari; Samprit Banerjee; Patricia A Arean
Journal:  Am J Geriatr Psychiatry       Date:  2015-12-17       Impact factor: 4.105

2.  Psychotherapies for Late-Life Depression.

Authors:  Amanda R McGovern; Dimitris N Kiosses; Patrick J Raue; Victoria M Wilkins; George S Alexopoulos
Journal:  Psychiatr Ann       Date:  2014-03-01

3.  [The Research Domain Criteria (Rdoc), reductionism and clinical psychiatry].

Authors:  Luc Faucher; Simon Goyer
Journal:  Rev Synth       Date:  2016-12

4.  Reward learning impairment and avoidance and rumination responses at the end of Engage therapy of late-life depression.

Authors:  Lindsay W Victoria; Faith M Gunning; Jennifer N Bress; Danielle Jackson; George S Alexopoulos
Journal:  Int J Geriatr Psychiatry       Date:  2018-03-24       Impact factor: 3.485

5.  Building resilience through psychotherapy.

Authors:  Charles F Reynolds
Journal:  World Psychiatry       Date:  2019-10       Impact factor: 49.548

Review 6.  Strategies for dementia prevention: latest evidence and implications.

Authors:  Gopalkumar Rakesh; Steven T Szabo; George S Alexopoulos; Anthony S Zannas
Journal:  Ther Adv Chronic Dis       Date:  2017-06-27       Impact factor: 5.091

Review 7.  Advances in Psychotherapy for Depressed Older Adults.

Authors:  Patrick J Raue; Amanda R McGovern; Dimitris N Kiosses; Jo Anne Sirey
Journal:  Curr Psychiatry Rep       Date:  2017-09       Impact factor: 5.285

8.  Cognitive Reappraisal Intervention for Suicide Prevention (CRISP) for Middle-Aged and Older Adults Hospitalized for Suicidality.

Authors:  Dimitris N Kiosses; George S Alexopoulos; Greg Hajcak; William Apfeldorf; Paul R Duberstein; David Putrino; James J Gross
Journal:  Am J Geriatr Psychiatry       Date:  2017-12-27       Impact factor: 4.105

9.  Comparing engage with PST in late-life major depression: a preliminary report.

Authors:  George S Alexopoulos; Patrick J Raue; Dimitris N Kiosses; Joanna K Seirup; Samprit Banerjee; Patricia A Arean
Journal:  Am J Geriatr Psychiatry       Date:  2014-06-26       Impact factor: 4.105

10.  Community delivery of brief therapy for depressed older adults impacted by Hurricane Sandy.

Authors:  Jo Anne Sirey; Patrick J Raue; Nili Solomonov; Clara Scher; Alexandra Chalfin; Paula Zanotti; Jacquelin Berman; George S Alexopoulos
Journal:  Transl Behav Med       Date:  2020-08-07       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.